Drug-eluting stent

...therapy for raising HDL "good" cholesterol. Acquired Guidant's vascular business, providing Abbott with the current market-leading drug-eluting stent, XIENCE V(TM), and the world's first bioabsorbable drug-eluting stent to enter...

In this article: Niacin, Market capitalization, Chronic pain, Miles D. White, Cholesterol, Guidant, and Advanced Medical Optics

...growth rate in big pharma, 11% compared to Johnson&Johnson's 7%. Sales of its rheumatoid arthritis drug, Humira, is up 24%, Xience, a drug-eluting stent, is also performing well. Abbott's nutritional products division has grown by 10% and...

In this article: Jim Cramer, Johnson & Johnson, Herbalife, Abbott Labs, CSX, APA, UNP, XTO Energy, AAPL, and Microsoft

...than heartache in their future. The heart-rhythm devices acquired from Guidant should get a boost from a recent study, and its Promus drug-eluting stent is doing well. That stent is made by Abbott Labs (NYSE: ABT) as part of the deal that...

In this article: Guidant, NYSE, Boston Scientific, Abbott Labs, Johnson & Johnson, Pfizer, Fiscal year, Revenue, Eli Lilly, and Food and Drug Administration

By Susan Kelly Boston Scientific Corp <BSX.N> on Monday said it received regulatory approval to sell its new Promus Element drug-eluting stent in Europe, replacing the Promus stent it co-markets with Abbott Laboratories <ABT.N>. The...

In this article: Boston Scientific Corp, Abbott Laboratories, Europe, Platinum, European Union, United States, Everolimus, and American College of Cardiology

BOSTON SCIENTIFIC ANNOUNCES EUROPEAN APPROVAL AND LAUNCH OF PLATINUM CHROMIUM PROMUS® ELEMENT™ STENT SYSTEM Third-generation drug-eluting stent now available in CE Mark countries Natick, MA, November 2, 2009 /PRNewswire/ - Boston...

In this article: Platinum, Boston Scientific, FDA, European Union, Cobalt, American College of Cardiology, Polymer, and Securities Exchange Act of 1934

...prior expectations for market growth of 5 percent to 6 percent, and U.S. defibrillator growth of 3 percent, Elliott said. The U.S. drug-eluting stent market, in which Boston Scientific also participates, is stable, with U.S. procedures up...

In this article: Boston Scientific, Tax, U.S., NYSE, Senate Finance Committee, and New York Stock Exchange

...Scientific's key end markets, drug-eluting stents and cardiac rhythm management, are decelerating and we expect Boston Scientific's drug-eluting stent share to erode over the next few quarters," Biegelsen wrote in a note to investors.

In this article: Boston Scientific, Thomson Reuters, Abbott Laboratories, St. Jude Medical, Medtronic, Wells Fargo, and Natick, Mass

...U.S. market, the HPV vaccine war of 2010 will probably get lots of mention in the financial press. The same thing happens in the drug-eluting stent wars between Johnson & Johnson (NYSE: JNJ), Boston Scientific (NYSE: BSX), Abbott Labs (NYSE:...

In this article: Merck, Human papillomavirus, NYSE, GlaxoSmithKline, Johnson & Johnson, U.S., Cervical cancer, Cancer, Wart, and Boston Scientific

...Inc <MDT.N> on Tuesday said it has begun a feasibility study for a treatment for erectile dysfunction that uses a specially designed drug-eluting stent. The study, called Zen, is expected to enroll 50 subjects at up to 10 U.S. medical...

In this article: Medtronic, Levitra, Cialis, Viagra, PDE5 Inhibitors, and Coronary artery disease

...cardiologists in San Francisco, offered more evidence of clinical strengths that have helped make Xience the top-selling drug-eluting stent. Stents are tiny wire-mesh scaffolds used to prop open narrowed or blocked arteries.

In this article: Boston Scientific, Abbott Laboratories, Revascularization, Medtronic, and Johnson & Johnson